Can Platelet-Rich Plasma Ease Greater Trochanteric Pain?
Researchers in blinded trial on autologous platelet-rich plasma (PRP) found no significant benefit for pain relief or functional improvement. PRP injections have been suggested as a nonsurgical treatment for various musculoskeletal conditions, but most controlled studies have reported minimal or no effectiveness. In this U.K. study, researchers investigated PRP use in patients with greater trochanteric pain syndrome (GTPS), confirmed via MRI.
GTPS, previously referred to as trochanteric bursitis, often includes gluteus medius tendinopathy. Greater trochanteric pain syndrome (GTPS) is a painful condition that can impair a patient’s quality of life. If nonoperative measures fail, progressively more invasive treatment options may be required.
This clinical trial aimed to evaluate the effectiveness of ultrasound-guided leukocyte-rich platelet-rich plasma (LR-PRP) injections in the treatment of refractory GTPS caused by bursitis and/or gluteal tendinopathy. An ethically approved, adequately powered, double-blinded randomized controlled trial (RCT) was conducted to evaluate the clinical outcomes in randomized LR-PRP and placebo groups using the International Hip Outcome Tool-12 (iHOT-12), a visual analogue scale (VAS) for pain, the modified Harris hip score (mHHS), the EuroQol 5-Dimensions (EQ-5D) questionnaire, and the presence or absence of complications.
All injections were performed under ultrasound guidance into the trochanteric bursa and gluteus medius tendon. Results: The final analysis included 79 patients (39 in the LR-PRP and 40 in the placebo group; 73 female and 6 male; all Caucasian). Both the LR-PRP and the placebo group generally had improvement from baseline that was maintained to 12 months. The only deterioration in scores compared to baseline was seen in the LR-PRP group for the iHOT-12 at 12 months, the EQ-5D index at 3 and 6 months, and the EQ-5D VAS at all follow-up time points. However, there was no significant difference between the 2 groups at any follow-up point (p > 0.05).
A multivariable linear regression model, with adjustment for age, sex, body mass index, and preoperative baseline score, did not reveal any significant associations between iHOT-12 and EQ-5D score gains at 12 months and treatment. This randomized trial found no significant difference in outcomes between LR-PRP and placebo for the treatment of greater trochanteric pain up to 6 months following the intervention. As a result, we do not support the routine use of PRP for the treatment of this condition.
Reference:
Atchia, Ismael MBBS, MD, FRCP1,2; Ali, Mohammed MBBS, MD3; Oderuth, Eshan MBBS, BSc, MRCS, FRCS(Tr&Orth)4; Holleyman, Richard MBBS, MSc, FRCS(Tr&Orth)5; Malviya, Ajay PhD, FRCS(Tr&Orth), MSc, MRCS(Ed), MS1,2,6. Efficacy of Platelet-Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome: A Double-Blinded Randomized Controlled Trial. The Journal of Bone and Joint Surgery 107(5):p 444-451, March 5, 2025. | DOI: 10.2106/JBJS.24.00763
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.